Volcano presses on with vulnerable plaque trial:
This article was originally published in Clinica
Volcano Therapeutics has enrolled the first 20 patients into its international safety trial assessing its thermography catheter for detecting vulnerable plaque in coronary arteries. The study is being conducted in New Zealand, Germany and Italy and is expected to produce data to support regulatory filings for permission to commercialise the product. Investigators have so far reported that the device has performed as expected and met all safety endpoints, says the Laguna Niguel, California firm.